Changes in Serum IL-22 and Their Significance in Chronic Hepatitis B Patients Treated with Telbivudine

Qi WANG,Yu WANG,Ya LIU,Yuewu YAN,Juan YUAN,Juan MA,Zhenzhen WANG
2014-01-01
Abstract:Objective: To observe the changes in serum interleukin 22( IL-22) level of the patients with chronic hepatitis B( CHB) before and after telbivudine treatment. Methods: 84 cases of CHB were treated with telbivudine,with the serum IL-22 level measured by enzyme-linked immununosorbent assay( ELISA) and with the hepatic function tested as well before and after the treatment. 30 healthy individuals were taken as the control group. Results: Compared with that in the control group,the level of serum IL-22 rose significantly in CHB patients( P 0. 01); compared with those before the treatment,the levels of serum IL-22,HBV-DNA and ALT dropped in CHB patients after the treatment with telbivudine( P 0. 05). Conclusion: Telbivudine can lower the serum IL-22 level in CHB patients through inhibiting HBV reproduction and improving cellular immunity function in CHB patients.
What problem does this paper attempt to address?